The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Dental Practice Possibly Exposes 7,000 Patients to Hepatitis and HIV

Back to News Homepage

Next

$24 Million Win for Victims of Hepatitis C Outbreak

Top Drug Companies Agree to Joint Study for All-Oral Hep C Treatment

April 11, 2013

Print this page

Two leading pharmaceutical companies, Vertex and Bristol-Myers Squibb, have agreed to work together towards their common goal – an all-oral Hepatitis C treatment.

Vertex, Bristol-Myers Squibb partner on oral hepatitis C treatment

Saturday, April 6, 2013

By: Ira Kantor

Vertex Pharmaceuticals Inc. said today it has entered into a non-exclusive agreement with Bristol-Myers Squibb Company to conduct second, all-oral studies of the former’s VX-135 drug with the latter’s drug, daclatasvir, for the treatment of hepatitis C.

As part of the agreement, Vertex plans to conduct two of these studies of the combination, including an initial study in treatment-naive people with genotype 1 HCV infection planned for the second quarter of this year.

Continue reading this entire article:
http://bostonherald.com/business/healthcare/2013/04/vertex_bristol_myers_squibb_partner_on_oral_hepatitis_c_treatment

No Comments - be the first!
Share
Share

Previous

Dental Practice Possibly Exposes 7,000 Patients to Hepatitis and HIV

Back to News Homepage

Next

$24 Million Win for Victims of Hepatitis C Outbreak

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.